In connection with restructuring plan , the Company expects to incur up to $165M in non-recurring charges, the majority of which will be expensed in 2023. The realization of cost savings is expected to accelerate in the second quarter of 2023 and achieve the full run rate within 18 months. As noted, these cost savings will fund critical growth investments in 2023 and beyond, across areas such as the global commercial organization, information technology, and compliance enabling the Company to enhance and sustain profitability, accelerate enterprise digitalization, and win in aligners and implants.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on XRAY:
- Dentsply Sirona Announces Organizational Changes to Simplify Structure, Enhance Profitability, Improve Operational Performance and Drive Growth
- Dentsply Sirona price target raised to $35 from $29 at Piper Sandler
- Dentsply Sirona to Host Fourth Quarter and Full Year 2022 Conference Call on February 28th
- Dentsply Sirona weighing $1B split of Wellspect HealthCare, Bloomberg reports
- Report of Dentsply weighing Wellspect sale ‘could have legs to it,’ says Piper